{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Voloudakis G"],"funding":["BLRD VA","NIDA NIH HHS","NIA NIH HHS","NIAID NIH HHS","NIMH NIH HHS","Brain and Behavior Research Foundation","U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","Icahn School of Medicine at Mount Sinai","NIH HHS","NIGMS NIH HHS"],"pagination":["52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9441828"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1)"],"pubmed_abstract":["Recent efforts have identified genetic loci that are associated with coronavirus disease 2019 (COVID-19) infection rates and disease outcome severity. Translating these genetic findings into druggable genes that reduce COVID-19 host susceptibility is a critical next step. Using a translational genomics approach that integrates COVID-19 genetic susceptibility variants, multi-tissue genetically regulated gene expression (GReX), and perturbagen signatures, we identified IL10RB as the top candidate gene target for COVID-19 host susceptibility. In a series of validation steps, we show that predicted GReX upregulation of IL10RB and higher IL10RB expression in COVID-19 patient blood is associated with worse COVID-19 outcomes and that in vitro IL10RB overexpression is associated with increased vir"],"journal":["NPJ genomic medicine"],"pubmed_title":["A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility."],"pmcid":["PMC9441828"],"funding_grant_id":["S10 OD030463","S10 OD026880","R01 AG050986","K08 MH122911","COVID-19 Pilot Grant","T32 GM062754","R01 AG067025","I01 BX002395","R01 AG065582","I01 BX004189","K08MH122911","R01 MH109677","U01 DA048279","29350","T32 AI007180","U01 MH116442"],"pubmed_authors":["Hoagland D","Beckmann ND","Iyengar SK","Merad M","Venkatesh S","Dobrindt K","Jiang S","Akbarian S","Luoh SW","Lee JS","Lynch JA","VA Million Veteran Program COVID-19 Science Initiative","Voloudakis G","Cho K","Corvelo A","Mount Sinai COVID-19 Biobank","Hoffman GE","Argyriou S","Roussos P","Vicari JM","Brennand KJ","Bian J","Striker R","Fullard JF","Schadt EE","Zhang W","Higgins CA","tenOever BR","Charney AW","Gao L","Lee KM","Assimes TL"],"additional_accession":[]},"is_claimable":false,"name":"A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility.","description":"Recent efforts have identified genetic loci that are associated with coronavirus disease 2019 (COVID-19) infection rates and disease outcome severity. Translating these genetic findings into druggable genes that reduce COVID-19 host susceptibility is a critical next step. Using a translational genomics approach that integrates COVID-19 genetic susceptibility variants, multi-tissue genetically regulated gene expression (GReX), and perturbagen signatures, we identified IL10RB as the top candidate gene target for COVID-19 host susceptibility. In a series of validation steps, we show that predicted GReX upregulation of IL10RB and higher IL10RB expression in COVID-19 patient blood is associated with worse COVID-19 outcomes and that in vitro IL10RB overexpression is associated with increased vir","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-05-29T19:00:51.75Z","creation":"2025-02-19T03:29:10.899Z"},"accession":"S-EPMC9441828","cross_references":{"pubmed":["36064543"],"doi":["10.1038/s41525-022-00324-x"]}}